Back to top
more

Pediatrix Medical Group, Inc. (MD)

(Delayed Data from NYSE)

$10.56 USD

10.56
1,728,847

-0.31 (-2.85%)

Updated Sep 20, 2024 04:00 PM ET

After-Market: $10.56 0.00 (0.00%) 5:20 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value A Growth D Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (162 out of 251)

Industry: Medical Services

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Sapna Bagaria headshot

Healthcare Stock Q1 Earnings Due on May 7: ELAN, MD, MODV

by Sapna Bagaria

Varied companies across the vast healthcare space might have been affected differently by the COVID crisis during the first quarter.

Earnings Preview: Mednax (MD) Q1 Earnings Expected to Decline

by Zacks Equity Research

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Retain Mednax (MD) in Your Portfolio

by Zacks Equity Research

Riding high on strategic initiatives and telehealth medicine, MEDNAX (MD) holds potential to reap benefits for investors.

Mednax (MD) Up 31.6% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Mednax (MD) Ties Up With NightLight to Offer Better Pediatric Care

by Zacks Equity Research

Mednax (MD) collaborates with NighLight with an aim to offer enhanced pediatric care in Texas.

Tenet Healthcare (THC) Hits 52 Week High: Will the Rally Stay?

by Zacks Equity Research

Tenet Healthcare's (THC) shares display an upsurge as investors get optimistic about its latest strategic initiatives and cost-curbing measures.

Why Should You Add Community Health (CYH) to Your Portfolio?

by Zacks Equity Research

Riding high on telehealth services and cost-cutting measures, Community Health (CYH) holds potential to reap benefits for investors.

MEDNAX's (MD) Q4 Earnings Fall Shy of Estimates, Tumble Y/Y

by Zacks Equity Research

MEDNAX's (MD) fourth-quarter results reflect muted revenues caused by the COVID-19 pandemic.

Mednax (MD) Q4 Earnings and Revenues Miss Estimates

by Zacks Equity Research

Mednax (MD) delivered earnings and revenue surprises of -19.35% and -8.64%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Here's Why You Should Hold MEDNAX (MD) in Your Portfolio Now

by Zacks Equity Research

Riding high on its strategic efforts and cost-cutting measures, MEDNAX (MD) holds enough potential to reap benefits for investors.

Tenet Healthcare (THC) Up 126.9% in 6 Months: More Room for Rally?

by Zacks Equity Research

Tenet Healthcare's (THC) strategic measures and cost-controlling efforts are expected to drive its margins, which in turn, might inflate its share price.

Mednax (MD) Up 60.5% Since Last Earnings Report: Can It Continue?

by Zacks Equity Research

Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

MEDNAX's (MD) Q3 Earnings Meet Estimates, Revenues Miss

by Zacks Equity Research

MEDNAX's (MD) third-quarter results reflect muted revenues and high costs, partly offset by lower interest expense.

Mednax (MD) Lags Q3 Earnings and Revenue Estimates

by Zacks Equity Research

Mednax (MD) delivered earnings and revenue surprises of -7.50% and -13.87%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Mednax (MD) Q3 Earnings Expected to Decline

by Zacks Equity Research

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Why Should You Retain MEDNAX (MD) in Your Portfolio Now?

by Zacks Equity Research

Riding on restructuring as well as cost-cutting initiatives, MEDNAX (MD) holds potential to reap benefits for investors.

MEDNAX Divests Radiology Business to Focus on Core Operations

by Zacks Equity Research

MEDNAX (MD) reaches an agreement with Radiology Partners to sell its MEDNAX Radiology Solutions, which will lower its debt load and restructure its business.

MEDNAX (MD) Catches Eye: Stock Jumps 5.4%

by Zacks Equity Research

MEDNAX (MD) saw a big move last session, as its shares jumped more than 5% on the day, amid huge volumes.

Why Should You Hold on to Tenet Healthcare (THC) Stock?

by Zacks Equity Research

Riding high on divestitures and cost-reduction, Tenet Healthcare (THC) holds enough potential to reap benefits for yield-seeking investors.

Why Is Mednax (MD) Down 5.3% Since Last Earnings Report?

by Zacks Equity Research

Mednax (MD) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Tenet Healthcare Up 39% in a Year: Further Upside Left?

by Zacks Equity Research

Tenet Healthcare's (THC) strategic measures and cost-controlling efforts are expected to support its margins, which in turn, might perk up its share price.

MEDNAX's (MD) Q2 Earnings Surpass Estimates, Decline Y/Y

by Zacks Equity Research

MEDNAX's (MD) Q2 results reflect lower expenses, offset by soft revenues.

Mednax (MD) Q2 Earnings Top Estimates

by Zacks Equity Research

Mednax (MD) delivered earnings and revenue surprises of 113.33% and -13.83%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?

Analysts Estimate Mednax (MD) to Report a Decline in Earnings: What to Look Out for

by Zacks Equity Research

Mednax (MD) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Here's Why You Should Steer Clear of MEDNAX (MD) at Present

by Zacks Equity Research

Pressure from the COVID-19 impact on global economy and lack of solvency make MEDNAX (MD) an unattractive bet.